Clinical efficacy and safety of statins in managing cardiovascular risk

作者：Navin K. Kapur · 发表于：Vascular Health and Risk Management · 年份：2008 · DOI：10.2147/vhrm.s1653 · 被引用次数：141 · 研究领域：Lipoproteins and Cardiovascular Health、Health Systems, Economic Evaluations, Quality of Life、Diabetes, Cardiovascular Risks, and Lipoproteins

Since their introduction in the 1980s, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) have emerged as the one of the best-selling medication classes to date, with numerous trials demonstrating powerful efficacy in preventing cardiovascular outcomes. As our understanding of low-density lipoprotein cholesterol (LDL-C) and atherosclerosis continues to grow, the concept of 'lower is better' has corresponded with a more is better' approach to statin-based therapy. This review provides a detailed understanding of the clinical efficacy and safety of statins with a particular emphasis on the third generation drug, rosuvastatin.